GlassScriptPhysician profile
John Charles Steffek
NPI 1427181932
$14,242.24
in general payments reported to CMS, 2019-2025
27 companies · $1,467 in 2025
The $1,467 reported for 2025 was more than what 90% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,096 · 2020: $1,745 · 2021: $2,735 · 2022: $2,422 · 2023: $1,948 · 2024: $1,829 · 2025: $1,467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,243.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $1,871.33 | 2019-2025 | Qelbree, Qelbree |
| Sunovion Pharmaceuticals INC. | $1,581.43 | 2019-2022 | |
| Neos Therapeutics, LP | $1,562.57 | 2019-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Tris Pharma INC | $1,304.30 | 2019-2025 | Dyanavel Xr, Quillichew Er, Quillivant |
| Abbvie INC. | $1,187.23 | 2021-2025 | Vraylar |
| Ironshore Pharmaceuticals INC. | $1,144.70 | 2020-2024 | Jornay Pm |
| Corium, LLC | $987.95 | 2021-2025 | Azstarys |
| Alkermes, INC. | $918.68 | 2021-2024 | Lybalvi, Aristada |
| Takeda Pharmaceuticals U.S.A., INC. | $543.94 | 2020-2022 | |
| Vertical Pharmaceuticals, LLC | $422.97 | 2019-2025 | Relexxii |
| Validus Pharmaceuticals LLC | $412.25 | 2021-2025 | Equetro, Equetro, Raldesy |
| Allergan, INC. | $393.18 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $312.81 | 2020-2025 | Caplyta |
| Adlon Therapeutics L.P. | $312.29 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $277.11 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $231.67 | 2019-2023 | Rexulti |
| Axsome Therapeutics, INC. | $207.61 | 2025 | Auvelity |
| Shire North American Group INC | $117.51 | 2019 | |
| Collegium Pharmaceutical, INC. | $69.40 | 2025 | Jornay Pm |
| Jazz Pharmaceuticals INC. | $62.44 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $60.61 | 2025 | Fanapt, Hetlioz |
| Noven Therapeutics, LLC | $56.74 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $56.03 | 2022-2023 | Quviviq |
| Rhodes Pharmaceuticals L.P. | $54.77 | 2019 | |
| Janssen Pharmaceuticals, INC | $50.84 | 2019-2020 | |
| Aytu Biopharma, INC. | $23.98 | 2021 | |
| Alfasigma USA, INC. | $17.90 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Steffek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.